What is Adc Therapeutics Sa share price today?

Adc Therapeutics Sa (ADCT) share price today is {{live_price}}.

Can Indians buy Adc Therapeutics Sa shares?

Yes, Indians can invest in the Adc Therapeutics Sa (ADCT) from India. With INDmoney, you can buy Adc Therapeutics Sa at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Adc Therapeutics Sa at zero transaction cost.

How can I buy Adc Therapeutics Sa shares from India?

It is very easy to buy Adc Therapeutics Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adc Therapeutics Sa be purchased?

Yes, you can buy fractional shares of Adc Therapeutics Sa with INDmoney app.

What are the documents required to start investing in Adc Therapeutics Sa stocks?

To start investing in Adc Therapeutics Sa, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Adc Therapeutics Sa

Today’s highest price of Adc Therapeutics Sa (ADCT) is {{1_rba_end}}. Today’s lowest price of Adc Therapeutics Sa (ADCT) is {{1_rba_st}}.

What is today's market capitalisation of Adc Therapeutics Sa

Today's market capitalisation of Adc Therapeutics Sa ADCT is 303.6M

What is the 52 Week High and Low Range of Adc Therapeutics Sa

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Adc Therapeutics Sa is down from its 52 Week High?

Adc Therapeutics Sa (ADCT) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Adc Therapeutics Sa is up from its 52 Week low?

Adc Therapeutics Sa (ADCT) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Adc Therapeutics Sa?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Adc Therapeutics Sa

Dr. Ameet Mallik M.B.A., M.S. is the current Chief Executive Officer (CEO) of Adc Therapeutics Sa.

Adc Therapeutics Sa share price: ADCT Stock Price live today

Performance

$3.08
$3.14
$3.11
0.96%
Downside
Day's Volatility :1.91%
Upside
0.96%
$0.36
$6.04
$3.11
88.43%
Downside
52 Weeks Volatility :94.04%
Upside
48.51%

Returns

Period	Adc Therapeutics Sa	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.29%	3.6%	0.0%
6 Months	-33.33%	10.2%	0.0%
1 Year	343.56%	19.6%	0.0%
3 Years	-88.19%	16.8%	-23.0%

Highlights

Market Capitalization	303.6M
Book Value	-$1.36
Earnings Per Share (EPS)	-2.54
Wall Street Target Price	9.8

Profit Margin	0.0%
Operating Margin TTM	-166.81%

Return On Assets TTM	-19.73%
Return On Equity TTM	-705.53%

Revenue TTM	66.7M
Revenue Per Share TTM	0.78
Quarterly Revenue Growth YOY	-9.700000000000001%
Gross Profit TTM	35.1M
EBITDA	-137.5M
Diluted Eps TTM	-2.54
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	-4.6
EPS Estimate Next Year	-5.6
EPS Estimate Current Quarter	-0.46
EPS Estimate Next Quarter	-0.44

Analyst Recommendation

Buy

83%Buy

16%Hold

0

0%Sell

Based on 12 Wall street analysts offering stock ratings for Adc Therapeutics Sa(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

10

8

Hold

2

Sell

00

Analyst Forecast

What analysts predicted

Upside of 215.11%

Current $3.11

Target $9.80

Company Financials

	FY21	Y/Y Change
Revenue	33.9M	↑ 0.0%
Net Income	-230.0M	↑ 0.0%
Net Profit Margin	-678.2%	↑ 0.0%

	FY21	Y/Y Change
Revenue	33.9M	↑ 0.0%
Net Income	-230.0M	↑ 0.0%
Net Profit Margin	-678.2%	↑ 0.0%

	FY22	Y/Y Change
Revenue	209.9M	↑ 0.0%
Net Income	-155.8M	↑ 0.0%
Net Profit Margin	-74.22%	↑ 0.0%

	FY22	Y/Y Change
Revenue	209.9M	↑ 0.0%
Net Income	-155.8M	↑ 0.0%
Net Profit Margin	-74.22%	↑ 0.0%

	FY23	Y/Y Change
Revenue	69.6M	↑ 0.0%
Net Income	-240.1M	↑ 0.0%
Net Profit Margin	-345.11%	↑ 0.0%

	FY23	Y/Y Change
Revenue	69.6M	↑ 0.0%
Net Income	-240.1M	↑ 0.0%
Net Profit Margin	-345.11%	↑ 0.0%

	Q1 FY23	Q/Q Change
Revenue	19.0M	↓ 72.79%
Net Income	-59.4M	↑ 146.0%
Net Profit Margin	-312.9%	↓ 278.29%

	Q2 FY23	Q/Q Change
Revenue	19.3M	↑ 1.53%
Net Income	-47.1M	↓ 20.71%
Net Profit Margin	-244.34%	↑ 68.56%

	Q3 FY23	Q/Q Change
Revenue	14.5M	↓ 24.84%
Net Income	-47.8M	↑ 1.46%
Net Profit Margin	-329.86%	↓ 85.52%

	Q4 FY23	Q/Q Change
Revenue	16.8M	↑ 15.85%
Net Income	-85.0M	↑ 77.86%
Net Profit Margin	-506.44%	↓ 176.58%

	Q1 FY24	Q/Q Change
Revenue	18.1M	↑ 7.52%
Net Income	-46.6M	↓ 45.19%
Net Profit Margin	-258.16%	↑ 248.28%

	Q2 FY24	Q/Q Change
Revenue	17.4M	↓ 3.56%
Net Income	-36.5M	↓ 21.59%
Net Profit Margin	-209.9%	↑ 48.26%

	FY21	Y/Y Change
Total Assets	618.0M	↑ 0.0%
Total Liabilities	451.9M	↑ 0.0%

	FY21	Y/Y Change
Total Assets	618.0M	↑ 0.0%
Total Liabilities	451.9M	↑ 0.0%

	FY22	Y/Y Change
Total Assets	529.2M	↑ 0.0%
Total Liabilities	440.4M	↑ 0.0%

	FY22	Y/Y Change
Total Assets	529.2M	↑ 0.0%
Total Liabilities	440.4M	↑ 0.0%

	FY23	Y/Y Change
Total Assets	354.8M	↑ 0.0%
Total Liabilities	503.0M	↑ 0.0%

	FY23	Y/Y Change
Total Assets	354.8M	↑ 0.0%
Total Liabilities	503.0M	↑ 0.0%

	Q1 FY23	Q/Q Change
Total Assets	467.7M	↓ 11.62%
Total Liabilities	430.0M	↓ 2.37%

	Q2 FY23	Q/Q Change
Total Assets	507.3M	↑ 8.47%
Total Liabilities	515.9M	↑ 19.98%

	Q3 FY23	Q/Q Change
Total Assets	466.9M	↓ 7.96%
Total Liabilities	521.1M	↑ 1.01%

	Q4 FY23	Q/Q Change
Total Assets	354.8M	↓ 24.01%
Total Liabilities	503.0M	↓ 3.46%

	Q1 FY24	Q/Q Change
Total Assets	308.0M	↓ 13.2%
Total Liabilities	502.4M	↓ 0.12%

	Q2 FY24	Q/Q Change
Total Assets	371.8M	↑ 20.72%
Total Liabilities	503.4M	↑ 0.21%

	FY21	Y/Y Change
Operating Cash Flow	-233.4M	↑ 0.0%
Investing Cash Flow	-6.7M	↑ 0.0%
Financing Cash Flow	267.4M	↑ 0.0%

	FY21	Y/Y Change
Operating Cash Flow	-233.4M	↑ 0.0%
Investing Cash Flow	-6.7M	↑ 0.0%
Financing Cash Flow	267.4M	↑ 0.0%

	FY22	Y/Y Change
Operating Cash Flow	-136.8M	↑ 0.0%
Investing Cash Flow	-2.5M	↑ 0.0%
Financing Cash Flow	-593.0K	↑ 0.0%

	FY22	Y/Y Change
Operating Cash Flow	-136.8M	↑ 0.0%
Investing Cash Flow	-2.5M	↑ 0.0%
Financing Cash Flow	-593.0K	↑ 0.0%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-14.8M	↓ 71.65%
Investing Cash Flow	-661.0K	↑ 464.96%
Financing Cash Flow	-196.0K	↓ 91.99%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-36.8M	↑ 149.31%
Investing Cash Flow	-661.0K	↑ 0.0%
Financing Cash Flow	74.7M	↓ 38232.14%

	Q3 FY23	Q/Q Change
Operating Cash Flow	-34.0M	↓ 7.63%
Investing Cash Flow	-661.0K	↑ 0.0%
Financing Cash Flow	-2.3M	↓ 103.09%

Technicals Summary

Sell

Neutral

Buy

Adc Therapeutics Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adc Therapeutics Sa	1.3%	-33.33%	343.56%	-88.19%	-89.48%
Regeneron Pharmaceuticals, Inc.	-9.28%	10.06%	24.53%	74.0%	232.45%
Novo Nordisk A/s	-4.54%	-5.72%	21.59%	126.2%	349.01%
Alnylam Pharmaceuticals, Inc.	8.87%	102.98%	82.67%	44.83%	241.09%
Vertex Pharmaceuticals Incorporated	5.0%	20.77%	31.37%	158.16%	163.17%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adc Therapeutics Sa	NA	NA	NA	-4.6	-7.06	-0.2	NA	-1.36
Regeneron Pharmaceuticals, Inc.	26.41	26.41	1.37	44.9	0.17	0.08	NA	261.41
Novo Nordisk A/s	40.21	40.21	1.81	3.36	0.89	0.23	0.01	25.24
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.42	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.59	0.18	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adc Therapeutics Sa	Buy	$303.6M	-89.48%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$110.0B	232.45%	26.41	32.04%
Novo Nordisk A/s	Buy	$529.8B	349.01%	40.21	34.84%
Alnylam Pharmaceuticals, Inc.	Buy	$38.1B	241.09%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$128.7B	163.17%	32.84	-4.74%

Insights on Adc Therapeutics Sa

Decreasing Revenue
Revenue is down for the last 2 quarters, 18.05M → 17.41M (in $), with an average decrease of 3.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -85.03M → -36.54M (in $), with an average increase of 55.0% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 133.0%